Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
496
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Investigative Site
Québec, Canada
Investigative Site
Hillerød, Denmark
Investigative Site
Paris, France
Change from baseline in urinary albumin creatinine ratio after 24 weeks
Equal/more than 50% reduction from baseline in urinary albumin creatinine ratio after 24 weeks
Change from baseline in urinary albumin excretion rate after 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Investigative Centers, Germany
Investigative Site
Athens, Greece
Investigative Site
Rome, Italy
Investigative Site
Rotterdam, Netherlands
Investigative Site
Bucharest, Romania
Investigative Site
Moscow, Russia
...and 2 more locations